NASDAQ STOCK MARKET

IBTimes Logo

Immunogen Shares Hit New High on Breast Cancer Study Results

Shares of Immunogen Inc. (NASDAQ: IMGN) touched a new 52-week high and a 9-year high of $12.03 on Thursday. Roche Holding AG said an experimental drug T-DM1 was effective in a mid-stage study of breast cancer patients whose disease has spread.
IBTimes Logo

American Superconductor Shares Hit New Low on Lost Shipments

Shares of American Superconductor Corp. (NASDAQ: AMSC) touched a new 52-week low of $12.54 on Wednesday morning, as it expects to post a fourth quarter loss mainly reflecting the refusal by one of its customers to accept contracted shipments.
More news
IBTimes Logo

VeriSign to Repurchase More Shares: Analyst

Wedbush Securities expects VeriSign Inc. (NASDAQ: VRSN) to continue to return capital to investors through 2011. The brokerage maintained its neutral rating on shares of VeriSign with a price target of $38.

Pre-Market NASDAQ Movers (MSSR, VVUS, OREX, CIGX, OPTR, OVTI, DEPO, AMTD, LOGI, CHKP)

The top pre-market NASDAQ Stock Market gainers are: McCormick & Schmick's Seafood Restaurants, VIVUS, Orexigen Therapeutics, Star Scientific, and Optimer Pharmaceuticals. The top pre-market NASDAQ Stock Market losers are: OmniVision Technologies, DepoMed, TD AMERITRADE Holding, Logitech International, and Check Point Software Technologies.

Biogen Idec Shares Hit New High on Start of Late-Stage ALS Drug Trial

Shares of Biogen Idec Inc. (NASDAQ: BIIB) touched a new 52-week high of $73.53 on Thursday. The company and its partner Knopp Biosciences announced enrollment of the first patient in EMPOWER, a multi-national Phase III study evaluating the efficacy, safety and pharmacokinetics of dexpramipexole in patients with amyotrophic lateral sclerosis (ALS).

Synthesis Energy Shares Hit New High on China Investment

Shares of Synthesis Energy Systems, Inc. (NASDAQ: SYMX) touched a new 52-week high of $3.12 on Thursday. The company has agreed with China Energy Industry Holding Group Co. Limited for a cash investment of about $83.8 million to support the company's business strategy in China, including project development and investment.
Teva Pharmaceutical

Near-Term Generic For Teva's Copaxone Still Unlikely: Analyst

RBC Capital Markets continues to believe that Teva Pharmaceutical Industries Ltd.'s (NASDAQ: TEVA) generic Copaxone is unlikely in the near term. The brokerage also said FDA denied Copaxone Citizen Petition (CP) as it is premature to make a decision on generic approvability.

Pages

IBT Spotlight

We Help Businesses Find B2B Service Providers They Can Trust.